Supplementary Data File for "A Randomized, Double-blind, Phase III Study Assessing Clinical Similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis"

Published: 19 April 2024| Version 1 | DOI: 10.17632/bh6p4rk5j9.1
Contributors:
, Joanna Narbutt, Giampiero Girolomoni, Jan Brzezicki, Nataliya Reznichenko, Maria Agnieszka Zegadlo-Mylik, Grazyna Pulka, Magdalena Dmowska-Stecewicz, Elżbieta Kłujszo, Dmytro Rekalov, Lidia Rajzer,
,
,

Description

Supplementary Materials for the Paper "A Randomized, Double-blind, Phase III Study Assessing Clinical Similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis" that is published in the Journal of the American Academy of Dermatology (JAAD).

Files

Categories

Psoriasis, Randomized Clinical Trial, Therapeutic Equivalence, Monoclonal Antibody Therapy

Funding

Samsung Bioepis Co., Ltd

Licence